By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
CHOOSE YOUR LANGUAGE
CHOOSE YOUR LANGUAGE
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466
Mohammed Tawil was appointed as the head of Boehringer Ingelheim's China operations last January. The company's goals in China include launching 25 new treatments in Human Pharma and introducing 10 new products and indications in animal health by 2030. Another key task for Tawil is finding the right people.